에 대한 최신 뉴스 Innovative Ind Props (NYSE:IIPR) 주식

Innovative Ind Props

Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.

Innovative Industrial Properties, Inc. Common Stock

Innovative Industrial Properties Inc

Innovative Industrial Properties, Inc. 9.00% Series A Cumulative Redeemable Preferred Stock

Stephens &amp; Co. analyst Andrew Terrell reiterates Preferred Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFBC#NASDAQ">PFBC</a>) with a Equal-Weight and maintains $91 price target.

News

Price Target

Reiteration

Analyst Ratings

PFBC

Stephens & Co. Reiterates Equal-Weight on Preferred Bank, Maintains $91 Price Target

Piper Sandler analyst Christopher Raymond maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Neutral and lowers the price target from $135 to $115.

BIIB

Piper Sandler Maintains Neutral on Biogen, Lowers Price Target to $115

UBS analyst Kevin Caliendo maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Buy and raises the price target from $150 to $160.

UBS Maintains Buy on Cardinal Health, Raises Price Target to $160

WIIM

CDNS

Cadence Design Systems shares are trading higher after the company reported better-than-expected Q1 earnings and raised its FY25 guidance.

Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) is down 2% on the day, but its Layer-2 blockchain, Shibarium, is gaining in momentum <a href="https://www.benzinga.com/money/shiba-inu-price-prediction#:~:text=Average%20Prediction%3A%20%240.00010-,Maximum%20Prediction%3A%20%240.00010,on%20investment%20from%20current%20valuations.">with new developments</a>.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>&nbsp;$0.00001353</td>
<td>$7.97 billion</td>
<td>-1.9%&nbsp;</td>
<td>+5.3%&nbsp;</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.1778</td>
<td>$26.5 billion</td>
<td>&nbsp;-1.3%</td>
<td>+7.2%</td>
</tr>
<tr>
<td>Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>)</td>
<td>&nbsp;$0.058943&nbsp;</td>
<td>$3.8 billion</td>
<td>-0.5%&nbsp;</td>
<td>+8.5%&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Shiba Inu community figure Shib Knight <a href="https://x.com/army_shiba/status/1916930277982507244">noted</a> that SHIB is currently mimicking Dogecoin's historical price structure, a pattern that could precede significant upside if history repeats.
Echoing that bullish tone, trader Marcus Corvirus says SHIB "is ready to explode," adding that the current rally is gaining more strength than its February move.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24SHIB&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$SHIB</a> is waking up ~ The chart screams bullish! This move looks even stronger than February's rally. No doubts, no brakes — Shiba Inu is ready to explode&#8230;. <a href="https://t.co/karwGVMBc1">pic.twitter.com/karwGVMBc1</a>
&mdash; Marcus Corvinus (@CryptoBull009) <a href="https://twitter.com/CryptoBull009/status/1916106548117475626?ref_src=twsrc%5Etfw">April 26, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Statistics: According to Shibariumscan, daily transactions climbed from 3.2 million on March 30 to 4.51 million by April 28. 
Meanwhile, total wallet addresses have reached 199.3 million, putting Shibarium on the cusp of a massive 200 million milestone, which is a strong indicator of growing adoption.
March also marked a major achievement, with Shibarium crossing $1 billion in total transaction volume, reinforcing its role as one of the most active L2s in the space.
Data from IntoTheBlock shows large SHIB transaction volume surged by 28.7%, with the number of $100,000 transfers increasing from 86 to 99 in just 24 hours. 
Daily active addresses dipped 8.7%, suggesting a shift toward larger holders or institutional activity.
U.Today notes that 533.08 trillion SHIB is held across 133,340 wallets in the $0.000015–$0.000019 price range, with an average entry of $0.000017. This level serves as a critical resistance zone, likely defining SHIB's next major directional move.
Community News: In an X post on April 26, Shiba Inu marketing lead Lucie <a href="https://x.com/LucieSHIB/status/1916002468770480139">emphasized</a> the project&#8217;s long-term vision: "SHIB is not just a token, it's powered by purpose, by people, and by belief in something better." 
She added that the road up is not easy but &#8220;we&#8217;re not done.&#8221;
Shibarium Updates <a href="https://x.com/Shibizens/status/1916864303921066418">reiterated</a> that SHIB remains among the top ERC-20 tokens by holder count, with over 1.5 million unique wallet addresses backing the project. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44930938/dogecoin-jumps-7-shiba-inu-up-4-is-a-major-meme-rally-brewing">Dogecoin Jumps 7%, Shiba Inu Up 4%: Is A Major Meme Rally Brewing?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

$PEPE

$SHIB

Shiba Inu Down 2%: Can Shibarium's Explosive Growth Fuel A SHIB Rally?

Stephens &amp; Co. analyst Andrew Terrell reiterates Bank of Marin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRC#NASDAQ">BMRC</a>) with a Overweight and maintains $26 price target.

BMRC

Stephens & Co. Reiterates Overweight on Bank of Marin, Maintains $26 Price Target

<a href="https://www.kerrisdalecap.com/wp-content/uploads/2025/04/Dwave-Kerrisdale.pdf">https://www.kerrisdalecap.com/wp-content/uploads/2025/04/Dwave-Kerrisdale.pdf</a>

Short Sellers

Trading Ideas

QBTS

Watching D-Wave Quantum: Kerrisdale Capital Issues Report On Co

Coca-Cola Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) shares are <a href="https://www.benzinga.com/premarket">trading higher</a> on Tuesday after the soft drink company released first-quarter 2025 earnings.
According to<a href="https://www.benzinga.com/pressreleases/25/04/b45062020/coca-cola-reports-first-quarter-2025-results"> the report:</a>
<ul>
<li>First-quarter sales declined 1.77% year-on-year to $11.1 billion, missing the analyst consensus estimate of $11.14 billion.</li>
<li>Revenue performance included a 1% climb in concentrate sales and a 5% growth in price/mix. Unit case volume grew 2% in the quarter. Organic revenues increased 6%.</li>
<li>Organic revenue in Europe, Middle East and Africa jumped 7% in the first quarter, while in North America, it increased 3%.</li>
<li>Gross profit slipped 1% to $6.96 billion with a profit margin of 62.5%. </li>
<li>Operating margins expanded 1400 basis points to 32.9%</li>
<li>The comparable operating margin gained 140 basis points to 33.8%. </li>
</ul>
Also Read: <a href="https://www.benzinga.com/news/25/04/45039495/dominos-pizza-q1-operating-margin-shrinks-as-lower-income-consumers-feel-the-pinch">Domino&#8217;s Pizza Q1 Operating Margin Shrinks As Lower-Income Consumers Feel the Pinch</a>
Operating income for the quarter jumped 71% to $3.65 billion. Adjusted EPS of 73 cents <a href="https://www.benzinga.com/earnings">beat the consensus</a> estimate of 72 cents.
Operating cash flow used in the quarter was $5.2 billion. As of March 28, Coca-Cola held $8.4 billion in cash and equivalents.
"Despite some pressure in key developed markets, the power of our global footprint allowed us to successfully navigate a complex external environment," said CEO James Quincey.
Outlook: Coca-Cola expects 2025 organic revenue of 5% – 6%, and comparable currency neutral EPS growth of 7% – 9%. The company sees comparable EPS growth of 2% to 3% versus $2.88 in 2024.
The company anticipates adjusted EPS of $2.94 &#8211; $2.97 with an estimate of $2.96.
Coca-Cola sees free cash flow excluding the fairlife contingent consideration payment (non-GAAP) of approximately $9.5 billion.
For second-quarter, Comparable EPS (non-GAAP) percentage growth is expected to include a 5% to 6% currency headwind.
Price Action: Coca-Cola shares traded higher by 0.84% at $71.86 at last check Tuesday.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/25/04/45011035/meta-booz-allen-launch-space-llama-ai-system-for-space-station-operations">Meta, Booz Allen Launch &#8216;Space Llama&#8217; AI System For Space Station Operations</a></li>
</ul>
Image: Shutterstock

General

Coca-Cola Boasts Q1 EPS Beat As Revenue Jumps In Europe, Middle East And Africa

Stephens &amp; Co. analyst Russell Gunther reiterates Ameris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABCB#NYSE">ABCB</a>) with a Equal-Weight and maintains $63 price target.

ABCB

Stephens & Co. Reiterates Equal-Weight on Ameris, Maintains $63 Price Target

The IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) board of directors today declared an increase in the regular quarterly cash dividend to $1.68 per common share, payable June 10, 2025 to stockholders of record as of May 9, 2025.&nbsp;
This is the 30th year in a row that IBM has increased its quarterly cash dividend.&nbsp; IBM has paid consecutive quarterly dividends since 1916.
&nbsp;

Dividends

IBM Board Increases Regular Quarterly Cash Dividend To $1.68/Shr

Stephens &amp; Co. analyst Russell Gunther reiterates Amerant Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMTB#NYSE">AMTB</a>) with a Overweight and maintains $24 price target.

AMTB

Stephens & Co. Reiterates Overweight on Amerant Bancorp, Maintains $24 Price Target

Raymond James analyst Alexander Sklar maintains Weave Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEAV#NYSE">WEAV</a>) with a Strong Buy and lowers the price target from $20 to $17.

WEAV

Raymond James Maintains Strong Buy on Weave Communications, Lowers Price Target to $17

FOXO Technologies Inc. (NYSE:<a href="https://www.benzinga.com/stock/FOXO#NYSE">FOXO</a>)&nbsp;("FOXO" or the "Company"), today announced that effective 4.01pm Eastern Time, on April 28, 2025, (the "Effective Time"), the Company completed a 1 for 10 reverse stock split of its outstanding common stock. The Company's common stock will open for trading on Tuesday April 29, 2025, on a post-split basis and continue to trade under the symbol FOXO.
As a result of the reverse split, every 10 shares of the Company's common stock issued and outstanding on the Effective Time will be consolidated into one issued and outstanding share with no change in the nominal par value per share of $0.0001. No fractional shares will be outstanding following the Reverse Stock Split. Holders of fractional shares will be entitled to receive, in lieu of any fractional share, the number of shares rounded up to the next whole number.
Based on the number of shares outstanding on April 28, 2025, the reverse stock will reduce the number of shares of the Company's common stock from approximately 38.7 million pre-reverse split shares to approximately 3.87 million post-reverse-split.

FOXO

FOXO Technologies Completes 1 For 10 Reverse Stock Split Of Outstanding Common Stock

Raymond James analyst Alexander Sklar maintains PowerFleet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIOT#NASDAQ">AIOT</a>) with a Outperform and lowers the price target from $10 to $8.

AIOT

Raymond James Maintains Outperform on PowerFleet, Lowers Price Target to $8

President Donald Trump has now been back in the White House for 100 days, with Tuesday marking the 100th day of his second term, following his inauguration on <a href="https://www.benzinga.com/general/entertainment/25/01/43139381/how-many-people-watched-donald-trumps-2025-inauguration-spoiler-less-than-biden-four-years-ago" target="_blank" rel="noopener">January 20, 2025</a><a href="https://www.benzinga.com/general/entertainment/25/01/43139381/how-many-people-watched-donald-trumps-2025-inauguration-spoiler-less-than-biden-four-years-ago">.</a>
Here's a look at where Trump stands with his election promises, voter polls, signing of laws and executive orders and the stock market after his first 100 days.
Promises Made, Promises Kept?: Ahead of the<a href="https://www.benzinga.com/government/regulations/25/01/43085323/trump-sworn-in-as-47th-president-declares-golden-age-of-america-begins-right-now"> 2024 presidential election</a>, Trump made numerous campaign promises, including some that he said he would ensure were completed within his first 100 days.
Here were some of the larger campaign issues and where Trump stands today.
<ul>
<li>Immigration: still in progress, but has mostly done what he said he would do.</li>
<li>Bring down prices: mixed with gas and energy prices down, but the cost of groceries now rising related to tariffs.</li>
<li>Tariffs: Trump said he would deploy tariffs, and that's what he has done, with a 10% tariff on all imports and higher reciprocal tariffs on many countries. While the tariffs have been paused or changed multiple times, Trump's promise of tariffs came true.</li>
<li>Ukraine-Russia War: Trump promised to end the war in Ukraine on his first day in office, but that is far from being true. Still a work in progress, with Trump meeting with Ukrainian President Volodymyr Zelenskyy and talking to Russian President Vladimir Putin.</li>
<li>Men in Women's Sports: Trump promised to change rules for transgenders to keep men out of women's sports and this one he's done or is working on with an executive order signed to ban men from competing in women's sports.</li>
<li>Others: While the above were the larger campaign promises, Trump has also pardoned over 1,500 people, including those involved in the Jan. 6 attack on the U.S. Capitol, which was an election promise. Trump has also worked to end DEI initiatives in the U.S. government and had the Department of Government Efficiency focus on making job cuts and eliminating programs to achieve cost savings. Other promises of tax cuts, including no taxes on tips, no taxes on overtime pay, and no interest on car loans haven't happened yet.</li>
</ul>
A scorecard <a href="https://apnews.com/projects/trump-campaign-promise-tracker/">from </a>the Associated Press grades Trump's campaign promises as four kept, 15 in progress and five as "it's complicated. The scorecard above not counting the others category, shows two promises kept and three as in process or not done.
Read Also:<a href="https://www.benzinga.com/news/global/25/04/45047432/trump-says-i-run-the-country-and-the-world-yet-polls-plummet"> Trump Says &#8216;I Run The Country And The World,&#8217; Yet Polls Plummet</a>
Laws and Executive Orders: When it comes to signing executive orders, Trump has been busy, having signed <a href="https://www.federalregister.gov/presidential-documents/executive-orders/donald-trump/2025" target="_blank" rel="noopener">over </a>130 since becoming president. While this leads to the claim that Trump has been one of the most productive presidents in history, it's essential to understand that this is based on executive orders, not laws passed.
As reported by <a href="https://punchbowl.news/article/white-house/trump-bills-first-hundred-days/">Punchbowl</a>, Trump has signed fewer bills into law in his first 100 days than any other new president in the last 70 years. Since taking office, Trump has signed only five bills into law, with the main one being the Laken Riley Act and the others being a stopgap funding bill to avoid a government shutdown and Congressional Review Acts to overturn regulations from the previous administration.
To put the figure into perspective, the report highlights that in the first 100 days of his last presidency, Trump had signed 28 bills into law.
The White House likes to highlight the number of executive orders signed by Trump in the first day closing in on the total number signed by President Joe Biden (162) during his entire presidency, but some presidents don't sign as many executive orders and focus on signing bills into law.
Executive orders are used to tell federal agencies how to enforce laws as long as it does not violate the Constitution or any federal laws, which in some cases have already been tested by the courts.
Voter Polls: Trump won the 2024 presidential election in both the Electoral College vote (312 to 226) and the popular vote (49.8% to 48.3%). Trump also has majority control in both the House and Senate.
While Trump may have been popular with around 50% or more of voters ahead of the 2024 election, he has lost support in the first 100 days. Along with losing support and having lower favorability ratings, Trump is also losing approval in key categories like handling of the economy.
A recent Morning Consult <a href="https://pro.morningconsult.com/trackers/donald-trump-congress-policy-republicans-polling?utm_source=briefing&amp;utm_medium=email&amp;utm_campaign=washington_am&amp;utm_content=042225">poll </a>found that 49% of voters disapprove of Trump's handling of the economy, which marks his worst net approval rating in the category.
A recent New York Times/Siena College<a href="https://www.benzinga.com/news/25/04/45027947/trumps-second-term-viewed-as-chaotic-and-scary-by-majority-of-voters"> poll</a> uses words like "chaotic" and "scary" to describe Trump's first 100 days in office. In the poll 66% of voters say Trump's second term is "chaotic," while 59% say the second term is "scary."
When asked about specific issues in the poll, voters gave Trump negative ratings across all categories, with his actions on immigration getting the highest approval rating of 47%. Trump's overall approval rating in the poll was 42%.
A newer Associated Press-NORC Center for Public Affairs Research poll<a href="https://www.benzinga.com/markets/equities/25/04/45027881/trumps-approval-plummets-as-tariffs-bite-americans-expect-skyrocketing-prices-and-shrinking-wallets"> found that rising costs</a> and Trump's handling of the economy hurt his overall approval rating.
In the poll, around 60% of voters said they disapproved of Trump's handling of the economy, with nearly 75% predicting that tariffs will increase consumer prices.
Tariffs were negative in the poll, with 52% of voters saying they are against any tariffs and 59% of voters saying Trump took tariffs too far.
Trump didn't win the youth vote, but was able to take a larger percentage than Republican candidates had in recent presidential elections. Those same younger voters (aged 18 to 29) <a href="https://www.benzinga.com/news/events/25/04/44971154/trump-fails-to-impress-americas-young-shows-poll-as-they-still-favor-biden-only-15-think-us-on-right-track">are now speaking out </a>about the future of the country.
A new Harvard Youth Poll found that only 15% of young voters believe the nation is headed in the right direction. Fifty-one percent of the voters said the country is on the wrong track, with 31% currently unsure.
Trump's approval rating in the youth poll recently stood at 31%.
Stock Market Performance: The S&amp;P 500, tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), is down 7.8% from its closing price on January 17, when Biden was still in office, to its current price.
The ETF closed at $597.58 on Jan. 17 before opening at $600.12 on Jan. 21 with optimism from investors for Trump's next term.
The Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which tracks the Nasdaq 100, is down 9.5% over Trump's first 99 days in office. The ETF and index have fallen on tariff concerns, hurting the technology sector hard.
With Trump's first 100 days nearly complete, the president is setting new milestones, but not in a good way. &nbsp;
According to <a href="https://www.cnbc.com/2025/04/28/trumps-first-100-days-are-the-worst-for-the-stock-market-since-nixon.html">CNBC</a>, the 7.9% drop in the S&amp;P 500 through Friday was the worst start to a four-year term since Richard Nixon in 1973, citing data from CFRA Research.
In 1973, the S&amp;P 500 fell 9.9% in the first 100 days of Nixon&#8217;s presidency. For comparison, the S&amp;P 500 has an average return of 2.1% in the first 100 days of a presidency, dating back to 1944.
Also, keep in mind that recent presidents had some of the best stock market performances in their first 100 days in office. Here are the recent returns and their rating since 1944:
<ul>
<li>2009: Barack Obama, +8.4%, fourth best</li>
<li>2013: Barack Obama, +7.5%, sixth best</li>
<li>2017: Donald Trump, +5.0%, seventh best</li>
<li>2021: Joe Biden, +8.5%, third best</li>
<li>2025: Donald Trump, -7.9%, twentieth and second worst</li>
</ul>
Markets traded higher in November and December on the heels of Trump's win, with some of the largest companies in the world hitting new all-time highs. January and February also saw gains after Trump took office.
Attention shifted towards economic policies and foreign in March and April, with markets diving in April after Trump's tariff announcement.
What's Next: Trump's first 100 days represent a portion of the 1,461 days the president would have under his current term, or roughly 6.8%.
While the time marks only a small portion of Trump's term, the first 100 days are important because they often reveal what the entire four-year term could be about and how things may play out.
Industry experts <a href="https://www.franklintempleton.com/articles/2025/institute/quick-thoughts-trumps-first-100-days-economic-impact-and-market-insights">believe </a>that Trump and his administration have a "high tolerance" for market pain and are mainly focused on resetting the economy.
Trump and his team have oftentimes said there could be short-term pain in consumer prices and stock market gains, which is all a part of a plan to make Americans rich in the future.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent042825">Get Tips On What They Bought And Sold With Our Easy-to-Use Tool</a></li>
</ul>
Read Next:
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent042825"><img loading="lazy" decoding="async" width="1024" height="330" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28215932/Picture1-4-1024x330.png" alt="" class="wp-image-891898" style="width:920px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28215932/Picture1-4-1024x330.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28215932/Picture1-4-300x97.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28215932/Picture1-4-768x248.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28215932/Picture1-4.png 1430w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/45066479/rare-bullish-signal-just-flashed-on-wall-street-will-it-power-sp-500-to-6000">Rare Bullish Signal Just Flashed On Wall Street: Will It Power S&amp;P 500 To 6,000?</a></li>
</ul>
Photo: noamgalai/Shutterstock

Broad U.S. Equity ETFs

Politics

ETFs

Trump's First 100 Days: What He Delivered, Where He Fell Short, How Markets Reacted

U.S. stocks traded mixed this morning, with the Dow Jones index gaining more than 100 points on Tuesday.
Following the market opening Tuesday, the Dow traded up 0.35% to 40,369.59 while the NASDAQ fell 0.10% to 17,349.14. The S&amp;P 500 also fell, dropping, 0.03% to 5,527.22.
Check This Out: <a href="https://www.benzinga.com/25/04/45064976/top-3-industrials-stocks-which-could-rescue-your-portfolio-in-q2">Top 3 Industrials Stocks Which Could Rescue Your Portfolio In Q2</a>
Leading and Lagging Sectors Real estate shares jumped by 0.6% on Monday.
In trading on Monday, energy fell by 1.2%.
Top Headline
The Coca-Cola Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) reported better-than-expected earnings for its first quarter on Tuesday.
The company posted quarterly earnings of 73 cents per share which beat the analyst consensus estimate of 72 cents per share. The company reported quarterly sales of $11.10 billion which missed the analyst consensus estimate of $11.14 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>LogicMark, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) shares shot up 103% to $0.0262.</li>
<li>Shares of Damon Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMN#NASDAQ">DMN</a>)got a boost, surging 86% to $0.0070.</li>
<li>WW International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WW#NASDAQ">WW</a>) shares were also up, gaining 62% to $0.6686 after the company announced a pharmacy integration with Eli Lilly&#8217;s LillyDirect pharmacy provider, Gifthealth.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Incannex Healthcare Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IXHL#NASDAQ">IXHL</a>) shares dropped 77% to $0.1388.</li>
<li>Shares of Petros Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) were down 55% to $0.0259.</li>
<li>AGM Group Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGMH#NASDAQ">AGMH</a>) was down, falling 28% to $0.0965.</li>
</ul>
Commodities In commodity news, oil traded down 2% to $60.79 while gold traded down 0.9% at $3,318.10.
Silver traded up 1.8% to $33.595 on Tuesday, while copper rose 0.3% to $4.9030.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 gained 0.3%, Germany's DAX 40 gained 0.6% and France's CAC 40 fell 0.3%. Spain's IBEX 35 Index fell 0.8%, while London's FTSE 100 rose 0.4%.
Asia Pacific Markets
Asian markets closed mixed on Tuesday, with China's Shanghai Composite falling 0.05%, Hong Kong's Hang Seng Index gaining 0.16% and India's BSE Sensex gaining 0.09%.
Economics
<ul>
<li>The number of job openings in the U.S. declined by 288,000 to 7.192 million in March, compared to market estimates of 7.48 million.</li>
<li>The S&amp;P CoreLogic Case-Shiller Home Price Index increased 4.5% year-over-year in February.</li>
<li>The FHFA house price index increased by 0.1% in February versus a revised 0.3% rise in January.</li>
<li>U.S. wholesale inventories climbed 0.5% month-over-month to $908 billion during March.</li>
<li>The U.S. trade deficit in goods increased to $162 billion in March compared to market estimates of a $146 billion gap.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45065334/amazon-com-to-253-here-are-10-top-analyst-forecasts-for-tuesday">Amazon.com To $253? Here Are 10 Top Analyst Forecasts For Tuesday</a> </li>
</ul>
Photo via Shutterstock

Earnings

Equities

Eurozone

Commodities

Intraday Update

Markets

AGMH

IXHL

LGMK

PTPI

US Stocks Mixed; Coca-Cola Posts Upbeat Earnings

AstraZeneca Plc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) on Tuesday reported first-quarter 2025 sales of $13.59 billion, up 7% year over year (+10% at constant currency), slightly missing the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $13.71 billion</a>, driven by double-digit growth in oncology and biopharmaceuticals.
The company&#8217;s adjusted EPADS&nbsp;reached&nbsp;$1.25, beating the consensus of $1.11. The adjusted EPS was $2.09 (1 ADR = 2 Common Shares).
AstraZeneca&#8217;s top business, oncology,&nbsp;<a href="https://www.astrazeneca.com/content/dam/az/PDF/2025/q1/Q1-2025-results-announcement.pdf" target="_blank" rel="noreferrer noopener">increased</a>&nbsp;10% (up 13% on constant currency) to $5.64 billion.
<ul>
<li>Tagrisso sales were up 5% to $1.68 billion (8% at CER), Imfinzi revenues were up 13% (+16%) to $1.26 billion, Calquence sales increased 6% to $762 million, Lynparza sales increased 3% (+8%) to $726 million, and Enhertu revenue was up 29% (39% at CER) to $596 million.</li>
<li>On Tuesday, The Committee for Medicinal Products for Human Use of the European Medicines Agency <a href="https://www.astrazeneca.com/media-centre/press-releases/2025/fixed-duration-calquence-recommended-in-eu-for-cll.html" target="_blank" rel="noreferrer noopener">recommended</a> approving a fixed-duration regimen of Calquence&nbsp;in combination with venetoclax, with or without obinutuzumab, for adult patients with previously untreated chronic lymphocytic leukemia.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/25/04/44851905/trumps-new-order-targets-drug-pricing-transparency-and-medicare-cost-reduction" rel="noreferrer noopener">Trump&#8217;s New Order Targets Drug Pricing Transparency And Medicare Cost Reduction</a>
Cardiovascular, Renal, and Metabolism (CVRM) sales increased 8% (up 12% at CER) to&nbsp;$3.25 billion.
<ul>
<li>Farxiga sales were up 11% (16% at CER) to $2.06 billion.</li>
</ul>
Respiratory &amp; Immunology (R&amp;I) sales increased 11% (13% CER) to $2.08 billion.
<ul>
<li>Symbicort revenues fell 6% (-3% CER) to $723 million, and Fasenra sales increased 17% (+19%) to $418 million.</li>
</ul>
Rare Disease drug sales decreased by 3% to&nbsp;$2.04 billion.
<ul>
<li>Ultomiris sales were up 22% (25% at CER) to $1.05 billion, offset by a 40% decline in Soliris (38% at CER) to $444 million.</li>
</ul>
China: In relation to the illegal drug importation <a href="https://www.wsj.com/health/pharma/astrazeneca-sales-earnings-rise-warns-of-mounting-legal-challenges-in-china-718ddef7">allegations</a>, AstraZeneca received an Appraisal Opinion from the Shenzhen City Customs Office regarding suspected unpaid importation taxes amounting to $1.6 million, referring to the Appraisal Opinion related to Enhertu.
<ul>
<li>A fine of between one and five times (up to $8 million) the amount of unpaid importation taxes may also be levied if AstraZeneca is found liable.</li>
<li>China&#8217;s sales accounted for 13% of quarterly sales, which is up 3% on a reported basis to&nbsp;<a href="https://www.benzinga.com/general/biotech/25/02/43527514/astrazeneca-q4-earnings-revenue-and-eps-beat-on-higher-cancer-and-respiratory-drug-sales-faces-4-5-million-potential-fine-in-china" target="_blank" rel="noreferrer noopener">$1.81 billion (+5% at CER)</a>.</li>
</ul>
AstraZeneca CEO Pascal Soriot said the company is &#8220;firmly committed to investing and growing in the U.S.&#8221; and continues to benefit from a &#8220;broad-based source of revenue and global manufacturing footprint.&#8221; 
AstraZeneca has 11 production sites in the U.S. covering small molecules, biologics as well as cell therapy. It also has two large R&amp;D sites in Gaithersburg MD and Cambridge MA.&#8221;
Guidance:&nbsp;For fiscal year 2025, AstraZeneca forecasts total revenue to increase by a high single-digit percentage and core EPS to increase by a low double-digit percentage.
On Tuesday, AstraZeneca <a target="_blank" href="https://www.astrazeneca.com/media-centre/press-releases/2025/update-on-capitello-280-phase-iii-trial.html" rel="noreferrer noopener">announced</a> the discontinuation of its CAPItello-280 Phase 3 trial of Truqap&nbsp;(capivasertib) in combination with docetaxel and androgen-deprivation therapy (ADT) compared to docetaxel and ADT with placebo in patients with metastatic castration-resistant prostate cancer.
The Independent Data Monitoring Committee reviewed and concluded that the&nbsp;Truqap&nbsp;combination was unlikely to meet the dual primary endpoints of radiographic progression-free survival and overall survival versus the comparator arm upon trial completion.
Price Action:&nbsp;AZN stock is down 0.13% at $69.84 during the premarket session on last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/04/45051380/plaintiff-sues-eli-lilly-johnson-johnson-over-alleged-breast-cancer-risk-linked-to-antipsychotic-medications" target="_blank" rel="noreferrer noopener">Plaintiff Sues Eli Lilly, Johnson &amp; Johnson Over Alleged Breast Cancer Risk Linked To Antipsychotic Medications</a></li>
</ul>
Image: Shutterstock

Biotech

Large Cap

Guidance

Health Care

Movers

AstraZeneca Q1 Earnings Rise, But China Drug Allegations May Lead To $8 Million Penalty

New Plan Latest Addition to Company's Comprehensive Benefits, Including Minimum $20 Starting Wage, Market-Leading Retirement Contributions and Tuition-Free Education
STAMFORD, Conn., April 29, 2025 /PRNewswire/ --&nbsp;Charter Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) today announced the launch of an Employee Stock Purchase Plan (ESPP), designed to encourage and reward employee tenure and empower its workforce to share in the Company's success. Eligible employees will now have the opportunity to purchase Charter stock through payroll deductions and will receive matching Restricted Stock Units (RSUs) based on their years with Charter.

CHTR

Charter Communications Launches ESPP, Offering Employees Stock Purchase And Tenure-Based RSUs

Raymond James analyst Patrick Tyler Brown maintains Vulcan Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VMC#NYSE">VMC</a>) with a Outperform and lowers the price target from $300 to $295.

Raymond James Maintains Outperform on Vulcan Materials, Lowers Price Target to $295

Raymond James analyst Patrick Tyler Brown maintains Martin Marietta Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLM#NYSE">MLM</a>) with a Outperform and lowers the price target from $600 to $597.

Raymond James Maintains Outperform on Martin Marietta Materials, Lowers Price Target to $597

Legal

Press Releases

Class Action Filed Against Innovative Industrial Properties, Inc. (IIPR) Seeking Recovery for Investors – Contact The Gross Law Firm

Shareholders of Innovative Industrial Properties, Inc. Should Contact Levi & Korsinsky Before March 18, 2025 to Discuss Your Rights - IIPR

Small Cap

IIPR Investors Have Final Opportunity to Lead Innovative Industrial Properties, Inc. Securities Fraud Lawsuit with the Schall Law Firm

IIPR Lawsuit Lead Plaintiff Deadline Is March 18th- Contact the DJS Law Group to Discuss Your Rights

Levi & Korsinsky Notifies Shareholders of Innovative Industrial Properties, Inc.(IIPR) of a Class Action Lawsuit and an Upcoming Deadline

Innovative Industrial Properties, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. March 18, 2025 Deadline to file Lead Plaintiff Motion

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Innovative Industrial Properties

IIPR ALERT: Bragar Eagel & Squire, P.C. is Investigating Innovative Industrial Properties, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Comments

Innovative Ind Props

뉴스

에 대한 최신 뉴스 Innovative Ind Props (NYSE:IIPR) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌